June 05, 2012 14:00 ET

Global Flow Cytometry Market to Jump to $4.9 Billion by 2017

NEW YORK, NY--(Marketwire - Jun 5, 2012) - cites in its newly published "Global Flow Cytometry Markets" report that the global flow cytometry market will jump to $4.9 billion by 2017. For more information, visit:

Flow cytometry can be categorized into three main types of applications: research, clinical diagnostic and pharmaceutical. The U.S., Europe and Japan account for 86% of the global flow cytometry market, but the emerging BRIC (Brazil, Russia, India and China) countries' share of the market is rapidly growing at a CAGR of 20%. Combined, the BD Biosciences division of Becton Dickinson and Beckman Coulter account for 49% of the flow cytometry market.

The "Global Flow Cytometry Markets" report covers:

  • CD4 T-Cell Testing
  • Multiplex Bead Assays
  • Stem Cell Research
  • Immunophenotyping of Leukemias and Lymphomas
  • Minimum Residual Disease (MRD)
  • Platelet Associated Immunoglobulin Assays
  • Paroxysmal Nocturnal Hemoblobinuria

The "Global Flow Cytometry Markets" report examines companies manufacturing flow cytometry equipment and supplies in the world. Companies covered include: AbD Serotec, ALPCO, Apogee Flow, Bay, BD, Beckman Coulter, BioCytex, Bioscience, BioVision, Blue Ocean, Cell Signaling, Cira Discovery, Clarient, Cytobank, CytonomeST, DVS, EMD Millipore, iCyt Mission, IntelliCyt, Life Technologies, Luminex, Miltenyi, Mindray, MiraiBio, Nihon Kohden, Partec, PointCare, Promega, Santa Cruzhnology, Sigma-Aldrich, Soft Flow, SouthernBiotech, Stratedigm, Sysmex, Takara, Techne, Tree Star, TTP LabTech, Union Biometrica, U.S. Biological, and Verity Software House.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit:

About is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information